Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials

Miroddi, M., Sterrantino, C., Simonelli, I., Ciminata, G., Phillips, R. S. and Calapai, G. (2015) Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials. Critical Reviews in Oncology/Hematology, 96(2), pp. 355-371. (doi: 10.1016/j.critrevonc.2015.06.004) (PMID:26160607)

Full text not currently available from Enlighten.

Abstract

The anti-Epidermal Growth Factor Receptor monoclonal antibodies (anti-EGFR MoAbs) are beneficial in the treatment of wild type (WT) KRAS colorectal cancer, but are burdened by serious toxicities. We conducted a systematic review and meta-analysis to determine incidence and relative risk (RR) of severe and life-threatening diarrhoea and mucositis in colorectal cancer patients and WT-KRAS subpopulation. PubMed and Embase were searched for trials comparing the same therapeutic regimens with or without anti-EGFR for colorectal cancer. Data on severe and life-threatening diarrhoea and mucositis were extracted from 18 studies involving 13,382 patients. Statistical analyses calculated incidence of AEs, RRs and 95% confidence intervals by using either random or fixed effects models. Patients receiving anti-EGFR MoAbs showed an increased risk of diarrhoea (RR: 1.66, CI 1.52–1.80) and mucositis (RR: 3.44, CI 2.66–4.44). The risk was similar among WT-KRAS patients. Prevention and risk reduction strategies of these AEs are mandatory to optimize clinical outcomes.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Ciminata, Dr Giorgio
Authors: Miroddi, M., Sterrantino, C., Simonelli, I., Ciminata, G., Phillips, R. S., and Calapai, G.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Health Economics and Health Technology Assessment
Journal Name:Critical Reviews in Oncology/Hematology
Publisher:Elsevier
ISSN:1040-8428
ISSN (Online):1879-0461
Published Online:24 June 2015

University Staff: Request a correction | Enlighten Editors: Update this record